慢性充血性心力衰竭的脂肪酸代谢特点(2)
[6]Lopaschuk GD,Beike DD,Gamble J,et al.Regulation of fatty acid oxidation in the mammalian heart in health and disease[J].Biochim Biophys Acta,1994,1213:2632276.
[7]Wisneski JA,Gertz EW,Neese RA,et al.Myocardial metabolism of free fattyacids.Studies with 14C2 labeled substrates in humans[J].J Clin Invest,1987,79:3592366.
[8]吴洪斌,胡盛寿,吴清玉,等.冠状动脉旁路移植术后围术期心肌缺血[.中国胸心血管外科临床杂志,2002,94:237-239.
[9]Gertz EW,Wisneski JA,Stanley WC,et al.Myocardial substrate utilization dur2ing exercise in humans. Dual Carbon2labeled carbohydrate isotope experiments[J].J Clin Invest,1988,82:201722025.
[10]Wisneski JA,Gertz EW,Neese RA,et al.Metabolic fate of extractedglucose innormal human myocardium[J].J ClinInvest,1985,76:181921827.
[11]RegitzV Shug AL Flock E Defectivemyocardial carnitine metabolism in conjestive heart failure secondary to dilated cardiomyopathy and to coronary hypertensive and valvular ChimicaActa，1985,1492:2632268。
[12]J ani S,Bergmann SR.Metabolic modulation of myocardial ische2mia[J].Curr Cadiol Rep,2006,8(2):123-130.
[13]Abozguia K,Clarke K,Lee L,et al.Modification of myocardial subst rate use as a t herapy for heart failure[J].Nat Clin PractCardiovasc Med,2006,3(9):490-498.
[14]Hadj A,Pepe S,Marasco S,et al.The principles of metabolict herapy for heart disease [J].Heart Lung Circ,2003,12(Supp12):S55-S62.
[15]Razegh i P,Young M E,A lcom JL,et al.M etabo lic gent ex2p ression in fetal and failing human heart [J].C ircu lation,2001,104(24):2923-2927., 百拇医药(王洪良 王秀丹 王同成 王广山)
[7]Wisneski JA,Gertz EW,Neese RA,et al.Myocardial metabolism of free fattyacids.Studies with 14C2 labeled substrates in humans[J].J Clin Invest,1987,79:3592366.
[8]吴洪斌,胡盛寿,吴清玉,等.冠状动脉旁路移植术后围术期心肌缺血[.中国胸心血管外科临床杂志,2002,94:237-239.
[9]Gertz EW,Wisneski JA,Stanley WC,et al.Myocardial substrate utilization dur2ing exercise in humans. Dual Carbon2labeled carbohydrate isotope experiments[J].J Clin Invest,1988,82:201722025.
[10]Wisneski JA,Gertz EW,Neese RA,et al.Metabolic fate of extractedglucose innormal human myocardium[J].J ClinInvest,1985,76:181921827.
[11]RegitzV Shug AL Flock E Defectivemyocardial carnitine metabolism in conjestive heart failure secondary to dilated cardiomyopathy and to coronary hypertensive and valvular ChimicaActa，1985,1492:2632268。
[12]J ani S,Bergmann SR.Metabolic modulation of myocardial ische2mia[J].Curr Cadiol Rep,2006,8(2):123-130.
[13]Abozguia K,Clarke K,Lee L,et al.Modification of myocardial subst rate use as a t herapy for heart failure[J].Nat Clin PractCardiovasc Med,2006,3(9):490-498.
[14]Hadj A,Pepe S,Marasco S,et al.The principles of metabolict herapy for heart disease [J].Heart Lung Circ,2003,12(Supp12):S55-S62.
[15]Razegh i P,Young M E,A lcom JL,et al.M etabo lic gent ex2p ression in fetal and failing human heart [J].C ircu lation,2001,104(24):2923-2927., 百拇医药(王洪良 王秀丹 王同成 王广山)